Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cognition Therapeutics Inc
(NQ:
CGTX
)
0.4219
+0.0119 (+2.90%)
Streaming Delayed Price
Updated: 9:55 AM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cognition Therapeutics Inc
< Previous
1
2
3
Next >
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
September 03, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
August 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update
August 08, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results
August 05, 2024
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients
July 29, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
July 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
July 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 21, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
May 07, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
April 29, 2024
- Top-line Results Expected in the Second Half of 2024 -
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease
April 22, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference
April 02, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024
April 01, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
BioMedNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering
March 15, 2024
Via
Investor Brand Network
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results
March 15, 2024
Conference Call and Live Audio Webcast Scheduled for March 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock
March 14, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces Proposed Public Offering of Common Stock
March 11, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies
March 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
February 26, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812
February 06, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics CEO Issues Letter to Shareholders
January 04, 2024
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens
November 16, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases
November 15, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
November 07, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
October 27, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
October 24, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
October 16, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
September 07, 2023
From
Cognition Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.